Oxurion (ENXTBR:OXUR) - Share price, News & Analysis

OXUR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

OXUR Stock Overview

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 3 more risks

Oxurion Competitors

Bone Therapeutics

ENXTBR:BOTHE

€5.8m

MDxHealth

ENXTBR:MDXH

€127.9m

Immuron

ASX:IMC

AU$21.4m

Midatech Pharma

AIM:MTPH

UK£11.1m

Price History & Performance

Summary of all time highs, changes and price drops for Oxurion
Historical stock prices
Current Share Price	€0.32
52 Week High	€2.59
52 Week Low	€0.28
Beta	0.76
1 Month Change	-18.97%
3 Month Change	-47.51%
1 Year Change	-84.88%
3 Year Change	-88.87%
5 Year Change	-89.81%
Change since IPO	-93.19%

Shareholder Returns

	OXUR	BE Biotechs	BE Market
7D	-1.3%	2.3%	1.6%
1Y	-84.9%	-14.1%	-6.3%

Return vs Industry: OXUR underperformed the Belgian Biotechs industry which returned -14.1% over the past year.

Return vs Market: OXUR underperformed the Belgian Market which returned -6.3% over the past year.

Price Volatility

Is OXUR's price volatile compared to industry and market?
OXUR volatility
OXUR Average Weekly Movement	17.9%
Biotechs Industry Average Movement	8.1%
Market Average Movement	4.7%
10% most volatile stocks in BE Market	8.1%
10% least volatile stocks in BE Market	2.6%

Stable Share Price: OXUR is more volatile than 90% of Belgian stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: OXUR's weekly volatility has increased from 12% to 18% over the past year.

About the Company

Founded	Employees	CEO	Website
1991	42	Tom Graney	https://www.oxurion.com

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME.

Oxurion Fundamentals Summary

How do Oxurion's earnings and revenue compare to its market cap?
OXUR fundamental statistics
Market Cap	€16.15m
Earnings (TTM)	-€29.16m
Revenue (TTM)	€1.13m

14.4x

P/S Ratio

-0.6x

P/E Ratio

Is OXUR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
OXUR income statement (TTM)
Revenue	€1.13m
Cost of Revenue	€612.00k
Gross Profit	€516.00k
Other Expenses	€29.67m
Earnings	-€29.16m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 07, 2022

Earnings per share (EPS)	-0.57
Gross Margin	45.74%
Net Profit Margin	-2,584.93%
Debt/Equity Ratio	-1,068.1%

How did OXUR perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is OXUR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OXUR?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for OXUR. This is calculated by dividing OXUR's market cap by their current preferred multiple.
What is OXUR's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	€16.15m

OXUR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	16.2x
Enterprise Value/EBITDA	-0.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does OXUR's PS Ratio compare to its peers?

OXUR PS Ratio vs Peers

The above table shows the PS ratio for OXUR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	21.9x
BOTHE Bone Therapeutics	2.8x	n/a	€5.8m
MDXH MDxHealth	5.5x	24.6%	€127.9m
IMC Immuron	60.3x	n/a	AU$21.4m
MTPH Midatech Pharma	19.2x	n/a	UK£11.1m
OXUR Oxurion	14.4x	-31.3%	€16.1m

Price-To-Sales vs Peers: OXUR is good value based on its Price-To-Sales Ratio (14.4x) compared to the peer average (21.9x).

Price to Earnings Ratio vs Industry

How does OXUR's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Sales vs Industry: OXUR is good value based on its Price-To-Sales Ratio (14.4x) compared to the European Biotechs industry average (16.1x)

Price to Sales Ratio vs Fair Ratio

What is OXUR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OXUR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.4x
Fair PS Ratio	3.5x

Price-To-Sales vs Fair Ratio: OXUR is expensive based on its Price-To-Sales Ratio (14.4x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Share Price vs Fair Value

What is the Fair Price of OXUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OXUR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OXUR's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Take a look at our analysis of OXUR's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Oxurion regulatory filings.

Future Growth

How is Oxurion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

17.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXUR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OXUR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OXUR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OXUR's revenue is expected to decline over the next 3 years (-31.3% per year).

High Growth Revenue: OXUR's revenue is forecast to decline over the next 3 years (-31.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OXUR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Oxurion performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-2.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: OXUR is currently unprofitable.

Growing Profit Margin: OXUR is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: OXUR is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.

Accelerating Growth: Unable to compare OXUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OXUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).

Return on Equity

High ROE: OXUR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Discover strong past performing companies

Financial Health

How is Oxurion's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: OXUR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: OXUR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: OXUR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: OXUR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OXUR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OXUR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.3% each year

Discover healthy companies

Dividend

What is Oxurion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate OXUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OXUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OXUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OXUR's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OXUR has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure

CEO

Tom Graney (57 yo)

1.83yrs

Tenure

€473,000

Compensation

Mr. Thomas Graney, also known as Tom, C.F.A., is a Non-Executive Director at Mogrify Limited since November 2021. He serves as Director at Oxurion NV since August 2021. He serves as Chief Financial Officer...

CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD481.03K) is about average for companies of similar size in the Belgian market ($USD488.26K).

Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.

Leadership Team

Experienced Management: OXUR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: OXUR's board of directors are considered experienced (7.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/17 00:00
End of Day Share Price	2022/08/17 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31